Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity

Summary

Atherosclerotic lesions represent a hypoxic milieu. However, the significance of this milieu in atherothrombosis has not been established. We aimed to assess the hypothesis that vascular wall hypoxia promotes arterial thrombus formation. We examined the relation between vascular wall hypoxia and arterial thrombus formation using a rabbit model in which arterial thrombosis was induced by 0.5 %- cholesterol diet and repeated balloon injury of femoral arteries. Vascular wall hypoxia was immunohistochemically detected by pimonidazole hydrochloride, a hypoxia marker. Rabbit neointima and THP-1 macrophages were cultured to analyse prothrombotic factor expression under hypoxic conditions (1 % O2). Prothrombotic factor expression and nuclear localisation of hypoxia-inducible factor (HIF)-1α and nuclear factor-kappa B (NF-κB) p65 were immunohisto-chemically assessed using human coronary atherectomy plaques. Hypoxic areas were localised in the macrophage-rich deep portion of rabbit neointima and positively correlated with the number of nuclei immunopositive for HIF-1α and NF-κB p65, and tissue factor (TF) expression. Immunopositive areas for glycoprotein IIb/IIIa and fibrin in thrombi were significantly correlated with hypoxic areas in arteries. TF and plasminogen activator inhibitor-1 (PAI-1) expression was increased in neointimal tissues and/or macrophages cultured under hypoxia, and both were suppressed by inhibitors of either HIF-1 or NF-κB. In human coronary plaques, the number of HIF-1α-immuno-positive nuclei was positively correlated with that of NF-κB-immuno-positive nuclei and TF-immunopositive and PAI-1-immunopositive area, and it was significantly higher in thrombotic plaques. Vascular wall hypoxia augments the thrombogenic potential of atherosclerotic plaque and thrombus formation on plaques via prothrombotic factor upregulation.

Keywords

Atherothrombosis - hypoxia - hypoxia-inducible factor-1 - nuclear factor-κB - tissue factor

• References

• 1 Lee KW, Lip GY. Acute coronary syndromes: Virchow’s triad revisited. Blood Coagul Fibrinolysis 2003; 14: 605-625.
• 2 Yamashita A, Matsuda S, Matsumoto T. et al. Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits. Atherosclerosis 2009; 206: 418-426.
• 3 Reininger AJ, Bernlochner I, Penz SM. et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55: 1147-1158.
• 4 Hatakeyama K, Asada Y, Marutsuka K. et al. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 1997; 133: 213-219.
• 5 Oemar BS, Tschudi MR, Godoy N. et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97: 2494-2498.
• 6 Sobel BE, Woodcock-Mitchell J, Schneider DJ. et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221.
• 7 Monaco C, Andreakos E, Kiriakidis S. et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004; 101: 5634-5639.
• 8 Zawadzki C, Susen S, Richard F. et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in athero-sclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 2007; 195: e117-125.
• 9 Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
• 10 Sluimer JC, Gasc JM, van Wanroij JL. et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008; 51: 1258-1265.
• 11 Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010; 02: 336-361.
• 12 Yamashita A, Shoji K, Tsuruda T. et al. Medial and adventitial macrophages are associated with expansive atherosclerotic remodeling in rabbit femoral artery. Histol Histopathol 2008; 23: 127-136.
• 13 Matsuda S, Yamashita A, Sato Y. et al. Human C-reactive protein enhances thrombus formation after neointimal balloon injury in transgenic rabbits. J Thromb Haemost 2011; 09: 201-208.
• 14 Temma T, Ogawa Y, Kuge Y. et al. Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model. J Nucl Med 2010; 51: 1979-1986.
• 15 Bjornheden T, Levin M, Evaldsson M. et al. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 870-876.
• 16 Leppanen O, Bjornheden T, Evaldsson M. et al. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis 2006; 188: 323-330.
• 17 Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009; 218: 7-29.
• 18 Burke B, Giannoudis A, Corke KP. et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163: 1233-1243.
• 19 Parathath S, Mick SL, Feig JE. et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011; 109: 1141-1152.
• 20 Deguchi JO, Yamazaki H, Aikawa E. et al. Chronic hypoxia activates the Akt and beta-catenin pathways in human macrophages. Arterioscler Thromb Vasc Biol 2009; 29: 1664-1670.
• 21 Yan SF, Zou YS, Gao Y. et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A 1998; 95: 8298-8303.
• 22 Marsch E, Theelen TL, Demandt JA. et al. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. Arterioscler Thromb Vasc Biol 2014; 34: 2545-2553.
• 23 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
• 24 Eltzschig HK, Kohler D, Eckle T. et al. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113: 224-232.
• 25 Hatakeyama K, Hao H, Imamura T. et al. Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 2005; 95: 632-635.
• 26 Raghunath PN, Tomaszewski JE, Brady ST. et al. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-1443.
• 27 Yan SF, Mackman N, Kisiel W. et al. Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 2029-2035.
• 28 Pinsky DJ, Liao H, Lawson CA. et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102: 919-928.
• 29 Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008; 100: 969-975.
• 30 Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997; 78: 747-754.
• 31 O’Rourke JF, Pugh CW, Bartlett SM. et al. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem 1996; 241: 403-410.
• 32 Walmsley SR, Print C, Farahi N. et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 2005; 201: 105-115.
• 33 Rius J, Guma M, Schachtrup C. et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453: 807-811.
• 34 McCaffrey TA, Fu C, Du B. et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest 2000; 105: 653-662.
• 35 Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408.
• 36 Karshovska E, Zernecke A, Sevilmis G. et al. Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipo-protein E deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2540-2547.
• 37 Subramanian P, Karshovska E, Reinhard P. et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 2010; 107: 96-105.
• 38 Vink A, Schoneveld AH, Lamers D. et al. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis 2007; 195: e69-75.
• 39 Okami N, Kawamata T, Yamamoto G. et al. Laser microdissection-based analysis of hypoxia- and thioredoxin-related genes in human stable carotid plaques. Cardiovasc Pathol 2009; 18: 294-300.
• 40 Wilson SH, Best PJ, Edwards WD. et al. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002; 160: 147-153.
• 41 Chen F, Eriksson P, Kimura T. et al. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron Artery Dis 2005; 16: 191-197.
• 42 Semenza GL. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004; 96: 1173-1177 discussion 1170–1172.
• 43 Shindo J, Ishibashi T, Kijima M. et al. Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis 2001; 12: 573-579.
• 44 Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 2007; 27: 1248-1258.